http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CY-1116441-T1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C275-28 |
| filingDate | 2015-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21c7497cf238b559fafe842b4c9adc65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_deb847b6540128f1cfb39a6c4c54307d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e7c19212b87f16754e196b712f91fa0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_329cb5946751da531aaa8958cd2351ec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff44c2c937bab15d723574c234b3023e |
| publicationDate | 2017-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CY-1116441-T1 |
| titleOfInvention | DERIVATIVES AND RELATED COMPOUNDS AMIDION piperidine and piperazine-1-CARBOXYLIC ACID AND RELATED COMPOUNDS AS DIAMORFOTES OF YDROLASIS fatty acid amides (FAAH) FOR THE TREATMENT OF ANXIETY, ALGOUS AND OTHER DISEASES |
| abstract | Compounds of formula (I), wherein: Z is -N- or> CH, R1 is -H or -C1-4 alkyl, Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl , 4-pyrimidinyl, 5-pyrimidinyl or phenyl, each unsubstituted or substituted on a carbon atom of the ring with one or two groups of Ra, each of which is a group of Ra, independently selected from the group consisting of -C1-4 alkyl, -C2- 4 alkenyl, -OH, -C1-4 alkyl, halo, -CF3, -OCF3, -SCF3, -SH, -S (O) 0-2C1-4alkyl, -OSO2C1-4alkyl, -CO2C1-4alkyl, -CO2H, -COC1-4alkyl), -N (Rb) Rc, -SO2NRbRc, -NRbSO2Rc, -C (= O) NRbRc, -NO2, and -CN, where Rb and Rc are each independently -H or -C1-4 alkyl, and Ar2 as defined in the claims, serve as FAAH inhibitors. Such compounds can be used in pharmaceutical compositions and methods for the treatment of diseases, disorders and diseases mediated by the activity of fatty acid amide hydrolase (FAAH). Therefore, the compounds can be administered for the treatment e.g. stress, pain, inflammation, sleep disorders, eating disorders or motor disorders (such as multiple sclerosis). |
| priorityDate | 2004-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.